| Literature DB >> 31695427 |
Meichen Yin1, Jiayu Shen1, Shuqian Yu1, Jing Fei1, Xiaoqing Zhu1, Jiayao Zhao1, Lingyun Zhai1, Annapurna Sadhukhan1, Jianwei Zhou1.
Abstract
Tumor-associated macrophages (TAMs) that appear in every stage of cancer progression are usually tumor-promoting cells and are present abundantly in the tumor-associated microenvironment. In ovarian cancer, the overall and intratumoral M1/M2 ratio is a relatively efficient TAM parameter for predicting the prognosis of patients, especially for serous tissue type cancer. TAMs exhibit immunological checkpoint modulators, such as the B7 family and programmed death-ligand 1 (PD-L1), and play a key role in the development, metastasis and invasion of ovarian cancer, but the underlying mechanism is barely understood. Ovarian cancer is a severe gynecological malignancy with high mortality. Ovarian cancer-associated death can primarily be attributed to cancer metastasis. The majority of patients are diagnosed with wide dissemination in the peritoneum and omentum, limiting the effectiveness of surgery and chemotherapy. In addition, unlike other well-documented cancers, metastasis through vasculature is not a usual dissemination pathway in ovarian cancer. This review sheds light on TAMs and the main process and mechanism of ovarian cancer metastasis.Entities:
Keywords: alternative activated macrophage; classical activated macrophage; hematogenous metastasis; ovarian cancer; transcoelomic metastasis; tumor associated macrophages
Year: 2019 PMID: 31695427 PMCID: PMC6814357 DOI: 10.2147/OTT.S216355
Source DB: PubMed Journal: Onco Targets Ther ISSN: 1178-6930 Impact factor: 4.147
Figure 1Cytokines and chemokines that influence TAM transformation and function.
Abbreviations: VEGFA, vascular endothelial growth factor A; VEGFR, vascular endothelial growth factor receptor; CCL18, chemokine ligand 18; PITPNM3, Membrane-associated phosphatidylinositol transfer protein; CSF1, colony-stimulating factor; CSF1R, colony-stimulating factor receptor; PDGF, platelet-derived growth factor; EGF, epidermal growth factor; FGF, fibroblast growth factor; TGF-β, transforming growth factor-β; MMP9, matrix metallopeptidase 9; CXCL8, chemokine (C-X-C motif) ligand 8; uPA, urokinase plasminogen activator; uPAR, urokinase plasminogen activator receptor; TNF-α, tumor necrosis factor-α; MCP-1, methylcyclopropene-1; M-CSF, macrophage colony-stimulating factor; SR-A, scavenger receptor A; HIF-1, hypoxia-inducible factor.
Figure 2The process of transcoelomic and hematogenous metastasis of ovarian cancer.